Roche Holding AG (RHHBY)
| Market Cap | 332.52B +27.3% |
| Revenue (ttm) | 79.90B +1.5% |
| Net Income | 16.24B +55.6% |
| EPS | 20.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 20.47 |
| Forward PE | 16.27 |
| Dividend | 0.97 (1.87%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 1,558,790 |
| Open | 52.38 |
| Previous Close | 52.02 |
| Day's Range | 51.80 - 52.42 |
| 52-Week Range | 37.51 - 60.85 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | 56.66 (+9.17%) |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $56.66, which is an increase of 9.17% from the latest price.
News
Ionis Pharmaceuticals (IONS) Shares Drop After Roche Discontinues Trials
Ionis Pharmaceuticals (IONS) Shares Drop After Roche Discontinues Trials
Nurix Posts Wider Q2 Net Loss As Revenue Drops; Highlights $700 Mln Roche Deal
(RTTNews) - Nurix Therapeutics, Inc. (NRIX) reported financial results for the second quarter ended May 31, 2026, reflecting a wider net loss and a decline in revenue. In addition, the company provide...
Nurix (NRIX) Reports Q2 Revenue Miss, Highlights Roche Collaboration
Nurix (NRIX) Reports Q2 Revenue Miss, Highlights Roche Collaboration
Roche Secures CE Mark For Automated Elecsys IGRA TB Diagnostic Test
(RTTNews) - Roche (RHHBY) announced that it has received the CE Mark for its Elecsys Interferon Gamma Release Assay (IGRA) TB test, a blood-based diagnostic test for identifying tuberculosis infection...
Roche receives CE Mark for blood test to identify tuberculosis infection
Basel, 9 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that its Elecsys IGRA TB test has received the CE Mark, introducing a new blood testing solution for identifying tuberculosis in...
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
Roche presents new data in Alzheimer's disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
Basel, 7 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will present new data from its Alzheimer's disease portfolio at the Alzheimer's Association International Conference® 20...
Genentech and Roche Present New Data in Alzheimer's Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will present new data from its Alzheimer's disease...
Astex Enters Exclusive Collaboration With Genentech For Breast Cancer Therapy Program
(RTTNews) - Astex Pharmaceuticals, a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., has announced an exclusive, worldwide research collaboration and license agreement with Genentech, a mem...
Roche's (RHHBY) Divarasib Surpasses Competitors in Lung Cancer Trial
Roche's (RHHBY) Divarasib Surpasses Competitors in Lung Cancer Trial
Roche's Divarasib Meets Primary Endpoint In Phase 3 Krascendo 1 Study For Treating Lung Cancer
(RTTNews) - Roche Holdings AG (RHHBY), a pharmaceutical company, on Thursday announced that the Phase 3 Krascendo 1 trial for the KRAS12C-inhibitor Divasarib vs. sotorasib and adagrasib had met its pr...
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Experimental drug, divarasib, showed meaningful improvements in both patients' overall survival and the time they survived without the disease worsening.
Genentech's Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today positive results from the Phase III Krascendo 1 study evaluating diva...
[Ad hoc announcement pursuant to Art. 53 LR] Roche's divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Basel, 02 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive results from the phase III Krascendo 1 study evaluating divarasib, an investigational next-generation KRAS G12C inhibi...
Roche to set up digital technology hub in Hyderabad
Swiss Drugmaker’s Second Hub In India To Become Operational in Q1 Of 2027
Old cancer drug may help restore fertility for certain women
We also cover a large study that should allay fears of people who should be taking cholesterol-lowering statins.
Roche Secures FDA Priority Review Of Enspryng In Thyroid Eye Disease; Decision Due October 2026
(RTTNews) - Genentech, a member of Roche Holding AG (RHHBY), announced on Tuesday that it has secured the US Food and Drug Administration (FDA) priority review of its supplemental Biologics License Ap...
FDA Grants Priority Review To Genentech's Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted and gra...
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip
Swiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer, in a bid to challenge U.S. firm Illumina's leadership in next-generation sequencing.
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
Basel, 29 June 2026 — Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of AXELIOS 1 based on the innovative SBX technology, with a unique combination of accuracy, speed, flexibility, scal...
Swiss pharma at risk of US trade investigation, industry body says
The United States could open a trade investigation into Switzerland's pharmaceutical industry similar to the one initiated last week against Germany, the head of Swiss industry body Interpharma said...
Louth GAA FL Round-up - Div 2: O’Raghallaighs pick up vital points as Roche open six-point lead at the top
Exelixis Announces STELLAR-303 Trial Results For Zanzalintinib Combination
(RTTNews) - Exelixis, Inc. (EXEL) on Monday reported final analysis results from the phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with Roche's Tecentriq versus regorafenib in prev...
The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs
The investigation comes after Berlin said it would require drugmakers to offer bigger discounts on medicines.
U.S. opens tariff probe targeting Germany's drug pricing policies
The U.S. said the probe will examine whether "persistent underpayment" for medicines by Germany is discriminatory. "President Trump has made clear that American patients should not be shouldering a di...